Supplier News Breaks Archives
Mallinckrodt, Zogenix to cease co-promotion pact
January 10th, 2014
ST. LOUIS and SAN DIEGO – Mallinckrodt and Zogenix are ending their co-promotion agreement for migraine treatment Sumavel DosePro.
The companies said Thursday that Mallinckrodt's promotion of Zogenix's Sumavel DosePro will end Jan. 31.
With a needle-free delivery system, Sumavel DosePro (sumatriptan injection) was Zogenix's first commercial product and was launched in January 2010 for the acute treatment of migraine and cluster headache. Plans call for Zogenix, as of Feb. 1, to assume full responsibility for the commercialization of the brand, with a focus on headache specialists, pain specialists and neurologists who treat a significant number of migraine patients.
"The end of our co-promotion agreement with Zogenix will allow our field sales team to focus on promoting our current and future products in the pain space," stated Mark Trudeau, president and chief executive officer at Mallinckrodt. "We have enjoyed a successful collaboration with Zogenix and wish them continued success with their products."
Mallinckrodt said it entered the co-promotion agreement with Zogenix on June 7, 2012. Under the agreement, Mallinckrodt's U.S. sales force sold Sumavel DosePro to its customer base of prescribers. Zogenix continued to record all product revenue, and Mallinckrodt was compensated based on a percentage of net sales from prescriptions generated by Mallinckrodt.
The original agreement was to slated to run through June 30, 2014. Zogenix said Thursday that the early termination is timed to precede the previously disclosed expansion of its sales force planned in February 2014.